Quotables
"The wireless music box has no imaginable commercial value. Who would pay for a message sent to nobody in particular?"
David Sarnoff, American radio pioneer ; 1921
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8110180 | Method of use of cytokine ZALPHA11 ligand Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of ... | 02/07/2012 |
| 8101166 | Methods for the treatment of IL-1β related diseases Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subjec... | 01/24/2012 |
| 8084021 | Recombinant human albumin-interleukin-11 fusion protein with long-lasting biological effects Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide h... | 12/27/2011 |
| 8034327 | Hyperglycosylated IL-7, preparation and uses The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well ... | 10/11/2011 |
| 8034326 | IL-21 variants IL-21 variant are provided wherein amino acids have been deleted and/or substituted in the region consisting of amino acid No. 65-96. ... | 10/11/2011 |
| 8034790 | Use of MDA-7 to inhibit pathogenic infectious organisms Methods of suppressing or preventing an infection of a subject by a pathogen that involve administering to the subject a composition that includes a therapeutically effective amount of an MDA-7 polypeptide or a nucleic acid encoding the MDA-7 polypeptide, and a phar... | 10/11/2011 |
| 8029775 | Methods of determining dose of IL-31 agonist to treat pulmonary inflammation Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proinflammatory cytokines and include admini... | 10/04/2011 |
| 8022037 | Skin wound healing compositions and methods of use thereof A wound healing composition comprising an amount of heat shock protein effective to promote wound healing and a method thereof to apply the composition. A preferred heat shock protein is either full-length hsp90α or the middle domain plus the charged sequence of hs... | 09/20/2011 |
| 8012465 | Methods for treating renal cell carcinoma Methods for treating renal cell carcinoma using low doses of IL-2 are disclosed. In particular, the invention relates to methods of treating metastatic renal cell carcinoma in patients who are renally impaired and/or intolerant of high dose IL-2 therapy. The therape... | 09/06/2011 |
| 8007776 | Vaccine composition comprising interleukin-15 (IL-15) Vaccine composition containing IL-15 for active immunization to treatment diseases related to over-expression of this cytokine. The technical aim pursued in this invention is to inhibit IL-15 activity through development of a therapeutic vaccine which elicits IL-15 ... | 08/30/2011 |
| 8003090 | Method for inhibiting a microvascular complication by administering IL-6 The present invention relates to the use of IL-6 or a fragment, variant, fusion protein, functional derivative or salt thereof in microvascular complications. ... | 08/23/2011 |
| 7998468 | Cytokine zalpha11 ligand antibodies Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of ... | 08/16/2011 |
| 7993638 | Cancer treatment combining lymphodepleting agent with CTLs and cytokines In a cancer treatment combining cell therapy with chemotherapy, autologous CD8+ T cells are obtained from a patient, activated ex vivo by contacting them with xenogenic antigen presenting cells loaded with selected peptide antigen, thereby generating anti... | 08/09/2011 |
| 7994114 | Chemokine mimetics synthesis and their use The present disclosure generally teaches compositions comprising SDF-1 mimetics and methods of using them to modulate an activity of a cell having an SDF-1 receptor by binding the SDF-1 receptor to an SDF-1 mimetic. The cell can be a hematopoietic cell, for example,... | 08/09/2011 |
| 7993637 | IL-11 muteins The present invention relates generally to the treatment of an interleukin-11 (IL-11)-mediated condition. More particularly, the present invention provides the use of modified forms of IL-11 which modulate IL-11 signaling in the treatment of IL-11-mediated condition... | 08/09/2011 |
| 7981409 | Method of reducing aging of skin by applying interleukin-1 alpha The present invention relates to cosmetic and dermatological methods for treating cellulite, reducing signs of aging skin, and treating stretch marks, the methods comprising applying/administering to the skin of a subject in need thereof the compositions comprising ... | 07/19/2011 |
| 7976835 | Methods and compositions for preventing and treating solid tumors Compositions and methods of preventing or treating a breast cancer are disclosed. The composition and method can utilize an endothelin B agonist and a chemotherapeutic agent as active ingredients to treat a solid tumor in mammals, including humans. Alternatively, th... | 07/12/2011 |
| 7959908 | Methods of treating viral infections using IL-21 Methods for treating mammals with infections, particularly viral infections using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide ... | 06/14/2011 |
| 7951359 | Compositions and methods for therapy or prevention of chemotherapy-induced neuropathy The present invention relates to the use of IL-6 in compositions and methods for therapy or prevention of chemotherapy-induced neuropathy (CIPN). More specifically, the invention relates to the use of a low dose of IL-6 for the treatment and/or prevention CIPN. ... | 05/31/2011 |
| 7951360 | Mutant interleukin-2 (IL-2) polypeptides The present invention relates to IL-2 mutants with increased affinity for the IL-2 alpha-receptor subunit (IL-2Rα). The invention thus includes IL-2 mutants with improved biological potency. The invention also includes methods for directed evolution of IL-2α using... | 05/31/2011 |
| 7943121 | IL-1β binding antibodies and fragments thereof An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an... | 05/17/2011 |
| 7939058 | Uses of IL-12 in hematopoiesis Methods for enhancing or stimulating hematopoiesis including the step of administering Interleukin-12 (IL-12) to yield hematopoietic recovery in a mammal in need. Preferred methods include the step of administering IL-12 as an adjuvant therapy to alleviate the hemat... | 05/10/2011 |
| 7927583 | Receptor based antagonists and methods of making and using The present invention provides a fusion polypeptide capable of binding a cytokine to form a nonfunctional complex. It also provides a nucleic acid sequence encoding the fusion polypeptide and methods of making and uses for the fusion polypeptide. ... | 04/19/2011 |
| 7928068 | Methods for using GEP, a chondrogenic growth factor and target in cartilage disorders The present invention relates to the expression and regulating growth factors in chrondrocytes and developing cartilage, particularly granulin-epithelin precursor (GEP). The invention relates to the modulation and manipulation of these growth factors, GEP, and/or th... | 04/19/2011 |
| 7914778 | Methods of treatment using IL-16 antagonist peptides The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can ... | 03/29/2011 |
| 7897145 | Methods for the treatment of renal failure The present invention relates to methods for treating renal failure. Particularly, the present invention relates to methods for treating renal failure by administering to a subject complexes that include a member of the IL-6 family linked to a soluble receptor of th... | 03/01/2011 |
| 7892530 | Treatment of tumor metastases and cancer Tumor metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of Interleukin-2 and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof. ... | 02/22/2011 |
| 7883695 | IL-12P40 and IL-B30 polypeptide complex Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided. ... | 02/08/2011 |
| 7858081 | IL-15 mutants having agonists/antagonists activity The present invention relates to the identification of an epitope in human Interleukin-15 (IL-15) that is responsible for binding to the interleukin-15 receptor α-chain. Two IL-15 regions are involved in the formation of this epitope: the first region (44 | 12/28/2010 |
| 7833520 | Method of using interferon-like protein ZCYTO21(IL-29) to treat hepatitis B The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypept... | 11/16/2010 |
| 7829075 | Method for expanding hematopoietic cells using cytokine zalpha11 ligand Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of ... | 11/09/2010 |
| 7829076 | Method of using interferon-like potein ZCYTO20 (IL-28A) or ZCYTO22(IL-28B) to treat hepatitis B The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class I... | 11/09/2010 |
| 7820156 | Method of treatment using a cytokine able to bind IL-18BP to inhibit the activity of a second cytokine The present invention relates to the use of a cytokine-1, preferably from the IL-1 family more preferably IL-1F7b, or an isoform, mutein, fused protein, functional derivative or fragment thereof capable of binding to IL-18BP or a mutein, fused protein, functional de... | 10/26/2010 |
| 7820155 | Methods of treating cancer comprising administering an interleukin-6 antibody variable region The present invention provides an isolated IL-6 antagonist including an antibody variable region that prevents IL-6 from binding to gp130. The present invention also provides compositions and methods for treating IL-6 related diseases based on the IL-6 antagonists o... | 10/26/2010 |
| 7807142 | Stabilized liquid polypeptide-containing pharmaceutical compositions Stabilized liquid polypeptide-containing pharmaceutical compositions are provided. The compositions comprise an amino acid base, which serves as the primary stabilizing agent of the polypeptide, and an acid and/or its salt form to buffer the solution within an accep... | 10/05/2010 |
| 7803361 | Therapeutic use of interleukin-2 mutants Interleukin-2 (IL-2) mutants having reduced toxicity, which include full-length IL-2, truncated forms of IL-2 and forms of IL-2 that are linked to another molecule are disclosed herein. Particular substitutions within IL-2, particularly within the permeability enhan... | 09/28/2010 |
| 7799322 | Use of IL-6 in liver injury The invention relates to the use of IL-6 in liver cirrhosis. ... | 09/21/2010 |
| 7799323 | Methods of using IL-31 to treat airway hyper-responsiveness and asthma Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proimflammatory cytokines and include admini... | 09/21/2010 |
| 7785580 | Modified IL-4 mutein receptor antagonists This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These... | 08/31/2010 |
| 7771714 | Medium comprising chicken leukemia inhibitory factor (LIF) The present invention is to provide a chicken LIF gene. Based on this genetic information, LIF protein derived from the chicken can be stably supplied and it solves the problems of the creation of transgenic chickens in the past. In addition, the present invention p... | 08/10/2010 |
